MRUS
Merus N.V.Company Information
- Company Name
- Merus N.V.
- CIK
- CIK0001651311
- Category
- Large accelerated filer
- Ticker: Exchange
- MRUS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MRUS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-29
- Last sale
- 2025-11-26
- Shares purchased (TTM)
- 77,203,103
- Shares sold (TTM)
- 89,805
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 33,412
- Shares outstanding
- 75,675,631
- Ownership
- 0.04%
Earnings Market Reaction
- Filing date
- 2025-10-31
- Price on filing date
- —
- 1-month reaction
- 0.95%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 367 | 443 | 197 | 293 | 433 | 629 | 178 | 204 | 242 | 101 | 103 | 148 | ||||||
| Marketable Securities Current | 268 | 267 | 261 | 244 | 199 | 158 | 159 | 150 | 147 | 164 | 139 | 142 | ||||||
Assets Current | ||||||||||||||||||
| Accounts Receivable Net Current | 19 | 17 | 14 | 1 | 1 | 2 | 59 | 2 | 3 | 3 | 5 | 4 | ||||||
| Assets Current | 692 | 768 | 522 | 569 | 666 | 807 | 410 | 369 | 405 | 283 | 258 | 306 | ||||||
| Prepaid Expense And Other Assets Current | 37 | 41 | 50 | 31 | 33 | 17 | 14 | 12 | 13 | 15 | 12 | 12 | ||||||
| Accounts Receivable Related Parties Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Marketable Securities Noncurrent | 181 | 182 | 180 | 187 | 151 | 59 | 61 | 57 | 57 | 47 | 46 | 36 | ||||||
| Property Plant And Equipment Net | 11 | 11 | 11 | 11 | 12 | 12 | 11 | 12 | 12 | 13 | 13 | 12 | ||||||
| Operating Lease Right Of Use Asset | 12 | 10 | 9 | 9 | 10 | 10 | 11 | 11 | 11 | 12 | 12 | 13 | ||||||
| Intangible Assets Net Including Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Equity Method Investments | 2 | 2 | 3 | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Assets Net | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 3 | 2 | 2 | ||||||
| Other Assets Noncurrent | 3 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | ||||||
| Assets | 904 | 980 | 731 | 783 | 845 | 892 | 498 | 455 | 492 | 364 | 339 | 377 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 8 | 21 | 9 | 4 | 6 | 4 | 7 | 5 | 4 | 8 | 5 | 10 | ||||||
| Accrued Liabilities And Other Liabilities | 45 | 41 | 43 | 44 | 36 | 41 | 33 | 38 | 36 | 31 | 40 | 36 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 87 | 92 | 89 | 87 | 80 | 81 | 78 | 69 | 64 | 66 | 75 | 79 | ||||||
| Taxes Payable Current | 7 | 0 | 8 | 7 | 5 | 2 | 2 | 2 | 0 | 1 | 2 | 2 | ||||||
| Operating Lease Liability Current | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deferred Revenue Current | 24 | 26 | 28 | 30 | 31 | 32 | 34 | 23 | 23 | 24 | 27 | 29 | ||||||
| Operating Lease Liability Noncurrent | 10 | 9 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 11 | 12 | 12 | ||||||
| Due To Related Parties Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Revenue Noncurrent | 33 | 38 | 38 | 39 | 52 | 55 | 60 | 20 | 24 | 29 | 34 | 39 | ||||||
| Liabilities | 129 | 138 | 135 | 135 | 141 | 145 | 149 | 99 | 99 | 106 | 121 | 129 | ||||||
| Due To Related Parties Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 5 | ||||||
| Additional Paid In Capital Common Stock | 2,066 | 2,039 | 1,686 | 1,665 | 1,641 | 1,616 | 1,161 | 1,126 | 1,118 | 949 | 877 | 871 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 775 | 842 | 596 | 648 | 703 | 747 | 349 | 356 | 393 | 257 | 218 | 247 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 19 | 18 | -32 | -55 | -7 | -39 | -30 | -23 | -37 | -27 | -26 | -30 | ||||||
| Retained Earnings Accumulated Deficit | -1,319 | -1,223 | -1,065 | -968 | -937 | -838 | -788 | -753 | -693 | -670 | -638 | -598 | ||||||
| Liabilities And Stockholders Equity | 904 | 980 | 731 | 783 | 845 | 892 | 498 | 455 | 492 | 364 | 339 | 377 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | ||||||
| Common Stock Shares Authorized | 105 | 105 | 105 | 105 | 105 | 105 | 68 | 68 | 68 | 68 | 68 | 68 | ||||||
| Common Stock Shares Issued | 76 | 76 | 69 | 69 | 68 | 68 | 59 | 58 | 58 | 50 | 46 | 46 | ||||||
| Shares Outstanding | 76 | 76 | 69 | 69 | 68 | 68 | 59 | 58 | 58 | 50 | 46 | 46 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMerus N.V. (MRUS) — SEC Financial Statements & Analysis
Merus N.V. (MRUS) is a pharmaceutical preparations company, incorporated in P7. Merus N.V. trades on Nasdaq as: MRUS. Merus N.V. (MRUS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-10-31. Based on that filing, On profitability, Merus N.V. posts an operating margin of -655.80%, a net margin of -673.31%, a Return on Equity (ROE) of -51.57%, a Return on Assets (ROA) of -43.59%, and a Return on Invested Capital (ROIC) of -109.25%. Per share, it reports EPS of $-5.04, diluted EPS of $-5.04, free cash flow per share of $-4.20, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 57.54% year-over-year, net income growth of 55.85% year-over-year, and EPS growth of 40.56% year-over-year. On the balance sheet, it maintains a current ratio of 7.97x, a quick ratio of 7.55x, working capital of $605.13M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.14, free cash flow of $-317.87M (TTM), and net debt of $-367.49M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-5.04
- ROE TTM
- -51.57%
- ROA TTM
- -43.59%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-317.87M
- Net Revenue TTM Growth 1Y
- 57.54%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Merus N.V. in?
Merus N.V. (MRUS) operates in the Pharmaceutical Preparations industry.
What exchange does MRUS trade on?
Merus N.V. (MRUS) trades on the Nasdaq.
Where is Merus N.V. incorporated?
Merus N.V. is incorporated in Netherlands.
When was Merus N.V. (MRUS)'s most recent SEC filing?
Merus N.V. (MRUS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-10-31.
What is MRUS's EPS (earnings per share)?
Merus N.V. (MRUS)'s trailing twelve month EPS is $-5.04 as of 2025-09-30.
What is MRUS's ROE (return on equity)?
Merus N.V. (MRUS)'s trailing twelve month Return on Equity (ROE) is -51.57% as of 2025-09-30.
What is MRUS's ROA (return on assets)?
Merus N.V. (MRUS)'s trailing twelve month Return on Assets (ROA) is -43.59% as of 2025-09-30.
What is MRUS's ROIC (return on invested capital)?
Merus N.V. (MRUS)'s trailing twelve month Return on Invested Capital (ROIC) is -109.25% as of 2025-09-30.